Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / OVA1

OVA1

Basics

Attributes

QA State: Curated
Short Name:
HGNC Name:

The OVA1 diagnostic test is comprised of five biomarkers: CA125, transthyretin (prealbumin), apolipprotein A1 (Apo A-1), beta-2 microglobulin, and transferrin. OVA1 is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) of Proteomic Biomarkers test that analyzes the serum levels of these five proteomic biomarkers. OVA1 is the first FDA approved test for assessing ovarian cancer risk in women previously diagnosed with an ovarian mass, and already scheduled for surgery. The OVA1 algorithm combines the results of these levels with information on the menopause status of the patient to classify the patient into a low- or high-risk group. The results of the OVA1 test can help determine patients needing referral to a gynecologic oncologist for their surgery.

Panel Details

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

OVA1 is intended for women 18 years old and older who have a previously identified ovarian mass. It is not intended to be used as a widespread screening tool or for diagnostic purposes. The OVA1 test is used in conjunction with other clinical and radiographic data to determine referral to a gynecologic oncologist.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.